All In Biotech

Drug Trial Radar · NCT07266558

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 And mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions That Put Them at High Risk for Severe Outcomes From COVID-19

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 30,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

30,000

Actual

Start

Nov 26, 2025

Primary completion

Jun 16, 2027

Study completion Jun 16, 2027

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.

Conditions

  • SARS-CoV-2

Interventions

  • mRNA-1273Biological

    Sterile liquid for injection

  • mRNA-1283Biological

    Sterile liquid for injection

  • PlaceboBiological

    0.9% sodium chloride (normal saline) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. VE of mRNA-1273 (Variant Formulation) to Prevent the First Event of COVID-19 after Study InjectionTime frame: Day 1 through Day 181
  2. Vaccine Efficacy (VE) of mRNA-1283 (Variant Formulation) to Prevent the First Event of COVID-19 after Study InjectionTime frame: Day 1 through Day 181
  3. Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Day 1 through Day 28
  4. Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs of Special Interest (AESIs), and AEs Leading to DiscontinuationTime frame: Day 1 through Day 181

Locations

150 sites in 1 country. Site status is shown where the registry gives one.

  • Accel Clinical Research

    Birmingham, Alabama

  • Cullman Clinical Trials

    Cullman, Alabama

  • AMR Clinical Mobile

    Mobile, Alabama

  • Velocity Clinical Research, Mobile

    Mobile, Alabama

  • Lenzmeier Family Medicine - Avacare

    Glendale, Arizona

  • Desert Clinical Research

    Mesa, Arizona

  • Velocity Clinical Research - Phoenix

    Phoenix, Arizona

  • Foothills Research Center/Avacare

    Phoenix, Arizona

  • Headlands Research Scottsdale

    Scottsdale, Arizona

  • Fiel Family and Sports Medicine / Avacare

    Tempe, Arizona

  • Avacare

    Colton, California

  • CenExel CNR

    Garden Grove, California

  • Velocity Clinical Research, Huntington Park

    Huntington Park, California

  • Velocity Clinical Research - San Diego - ERN - PPDS-Site Number:8400010

    La Mesa, California

  • Velocity Clinical Research - Los Angeles

    Los Angeles, California

  • Artemis Institute for Clinical Research

    Riverside, California

  • Peninsula Research Associates

    Rolling Hills Estates, California

  • Velocity Clinical Research -- Banning

    San Bernardino, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Tekton Research, LLC

    Denver, Colorado

  • Tekton Research, LLC

    Fort Collins, Colorado

  • Critical Care, Pulmonary and Sleep Associates, P.LLP/Avacare

    Lakewood, Colorado

  • Tekton Research, LLC

    Longmont, Colorado

  • New England Research Associates

    Bridgeport, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • Velocity Clinical Research-Washington, DC

    Washington D.C., District of Columbia

  • Hillcrest Medical Research, LLC

    DeLand, Florida

  • University Clinical Research-Deland, LLC d/b/a Accel Research Sites - Deland Clinical Research Unit

    DeLand, Florida

  • Suncoast Research Associates, LLC

    Doral, Florida

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida

  • Indago Research & Health Center, Inc

    Hialeah, Florida

  • CenExel Research Centers of America

    Hollywood, Florida

  • NextPhase Research Florida

    Hollywood, Florida

  • Health Awareness Inc.

    Jupiter, Florida

  • Sandhill Research, LLC d/b/a Accel Research Sites - Lakeland Clinical Research Unit

    Lakeland, Florida

  • Sandhill Research, LLC d/b/a Accel Research Sites- St. Pete-Largo Clinical Research Unit

    Largo, Florida

  • Accel Research Sites

    Maitland, Florida

  • Global Health Research Center, Inc.

    Miami Lakes, Florida

  • Suncoast Clinical Research

    New Port Richey, Florida

  • Headlands Research Orlando

    Orlando, Florida

Showing 40 of 150 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.